Parathion-methyl hapten, sibutramine hapten, parathion-methyl-sibutramine artificial antigen, antibody and detection kit
A novel methyl parathion-sibutramine artificial antigen and antibody system allows for simultaneous, sensitive, and rapid detection of both compounds, addressing the limitations of existing detection methods.
Patent Information
- Application Number
- CN202411172605.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-26
AI Technical Summary
Current methods for detecting methyl parathion and sibutramine lack a highly sensitive and rapid technique for simultaneous detection, with existing ELISA methods being limited and instrumental analysis being costly and time-consuming.
Development of methyl parathion and sibutramine haptens coupled with carrier proteins to create a methyl parathion-sibutramine artificial antigen, followed by immunization to produce a polyclonal antibody that can recognize both compounds with high specificity and sensitivity, integrated into a detection kit for immunoassay.
The method enables simultaneous, sensitive, and rapid detection of both methyl parathion and sibutramine, providing a reliable and efficient tool for on-site analysis.
Smart Images

Figure CN119060088A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of food safety detection, and in particular to a methyl parathion hapten, a sibutramine hapten, a methyl parathion-sibutramine artificial antigen and antibody, and a detection kit. Background Art
[0002] As a norepinephrine inhibitor, sibutramine can reduce weight by inhibiting the central nervous system and reducing appetite, but it can also cause adverse reactions such as anorexia, insomnia, and abnormal liver function, and may even cause cardiovascular and cerebrovascular diseases, neurological disorders, and nervous system damage. Therefore, the production, sale, and use of sibutramine preparations and their APIs have been banned.
[0003] Methyl parathion is a broad-spectrum organophosphorus insecticide that is widely used in pest control of economic crops such as fruit trees and tea. However, it is highly toxic and its residues in fruits can enter the human body through the food chain, causing serious toxic effects on the nervous system and immune system. Therefore, methyl parathion has been listed as a banned pesticide. However, due to its significant insecticide effect, methyl parathion is still abused.
[0004] Methyl parathion and sibutramine are both small molecules with no immune activity. They must be connected to protein molecules to induce an immune response in the body. Therefore, a reliable methyl parathion-sibutramine artificial antigen and a method for preparing it are urgently needed.
[0005] At present, the detection methods for methyl parathion and sibutramine mainly include instrumental analysis represented by high performance liquid chromatography and capillary electrophoresis, and immunoassay represented by enzyme-linked immunosorbent assay (ELISA). Although the instrumental analysis method can accurately detect samples, its sample pretreatment is complicated, the instruments and equipment are expensive, and the detection time is long, so it is only suitable for laboratory quantitative analysis. The immunoassay method is simple to operate, low in detection cost, and fast in detection speed. It is suitable for on-site large-scale rapid detection of samples, and can better meet the detection work of growers, enterprises and regulatory authorities.
[0006] At present, there are many ELISA methods for detecting methyl parathion, but there are few ELISA methods for detecting sibutramine. Based on the ELISA detection method of methyl parathion, a polyclonal antibody that can simultaneously identify methyl parathion and sibutramine is prepared and a corresponding ELISA rapid analysis method is established, thereby realizing the simultaneous detection of methyl parathion and sibutramine in samples by ELISA, which has important practical significance.
[0007] In view of this, the present invention is proposed. Summary of the invention
[0008] One of the purposes of the present invention is to provide a methyl parathion hapten which can obtain a novel artificial antigen structure after coupling with a carrier protein.
[0009] The second object of the present invention is to provide a method for preparing methyl parathion hapten, which has simple process and high success rate.
[0010] A third object of the present invention is to provide a sibutramine hapten.
[0011] A fourth object of the present invention is to provide a method for preparing sibutramine hapten, which has a simple process and a high success rate.
[0012] The fifth object of the present invention is to provide a methyl parathion-sibutramine artificial antigen, and the polyclonal antibody obtained from the artificial antigen can simultaneously recognize methyl parathion and sibutramine with better recognition ability.
[0013] The sixth object of the present invention is to provide a methyl parathion-sibutramine polyclonal antibody, which can simultaneously recognize two drugs, methyl parathion and sibutramine, with good specificity and high sensitivity.
[0014] The seventh object of the present invention is to provide an application of a methyl parathion-sibutramine polyclonal antibody, which solves the technical problem that there is a lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art.
[0015] The eighth object of the present invention is to provide a detection kit for methyl parathion and sibutramine, which can simultaneously identify two drugs, methyl parathion and sibutramine, with good specificity and high sensitivity.
[0016] The ninth object of the present invention is to provide an application of a detection kit for methyl parathion and sibutramine, which solves the technical problem of the lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art.
[0017] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:
[0018] In a first aspect, a methyl parathion hapten is provided, wherein the structural formula of the methyl parathion hapten is as shown in formula (I):
[0019]
[0020] In a second aspect, a method for preparing a methyl parathion hapten comprises the following steps:
[0021] O,O-diethylthiophosphoryl chloride reacts with p-hydroxybenzoic acid to obtain the methyl parathion hapten.
[0022] In a third aspect, a sibutramine hapten, the structural formula of the sibutramine hapten is as shown in formula (II):
[0023]
[0024] In a fourth aspect, a method for preparing a sibutramine hapten comprises the following steps:
[0025] 1-(4-chlorophenyl)cyclobutanecarbonitrile reacts under the action of isobutylmagnesium bromide and sodium borohydride to obtain the sibutramine hapten.
[0026] In a fifth aspect, a methyl parathion-sibutramine artificial antigen is obtained by coupling the above-mentioned methyl parathion hapten and the above-mentioned sibutramine hapten with a carrier protein through the active ester method.
[0027] Furthermore, the carrier protein includes bovine serum albumin and chicken ovalbumin.
[0028] In a sixth aspect, a methylparathion-sibutramine polyclonal antibody is obtained by immunizing an animal with the artificial antigen described in any one of the above items.
[0029] A seventh aspect provides a use of the above-mentioned methyl parathion-sibutramine polyclonal antibody in immunodetection of methyl parathion and sibutramine.
[0030] In an eighth aspect, a detection kit for methyl parathion and sibutramine is provided, wherein the detection kit comprises the methyl parathion-sibutramine polyclonal antibody described above.
[0031] A ninth aspect provides an application of the above-mentioned detection kit in immunoassay of methyl parathion and sibutramine.
[0032] Compared with the prior art, the present invention has at least the following beneficial effects:
[0033] The methyl parathion hapten provided by the invention can obtain a novel artificial antigen structure after being coupled with a carrier protein.
[0034] The method for preparing the methyl parathion hapten provided by the invention has simple process and high success rate.
[0035] The sibutramine hapten provided by the invention can obtain a novel artificial antigen structure after being coupled with a carrier protein.
[0036] The method for preparing the sibutramine hapten provided by the invention has simple process and high success rate.
[0037] The methyl parathion-sibutramine artificial antigen provided by the present invention is a novel artificial antigen structure. The polyclonal antibody obtained from the artificial antigen can simultaneously recognize methyl parathion and sibutramine, and has a good recognition ability.
[0038] The methyl parathion-sibutramine polyclonal antibody provided by the present invention can simultaneously identify two drugs, methyl parathion and sibutramine, with good specificity and high sensitivity, provides core raw materials for establishing a specific immunoassay method for methyl parathion and sibutramine, and has broad development prospects.
[0039] The application of the methyl parathion-sibutramine polyclonal antibody provided by the present invention solves the technical problem that there is a lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art.
[0040] The detection kit for methyl parathion and sibutramine provided by the invention can simultaneously identify two drugs, methyl parathion and sibutramine, and has good specificity and high sensitivity.
[0041] The application of the detection kit for methyl parathion and sibutramine provided by the invention solves the technical problem of lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0043] Figure 1 A schematic diagram of the synthesis process of methyl parathion hapten provided in one embodiment of the present invention;
[0044] Figure 2 A schematic diagram of the synthesis process of sibutramine hapten provided in one embodiment of the present invention;
[0045] Figure 3 The effect of combining methyl parathion first and then combining sibutramine at different concentrations on the inhibition rate provided by one embodiment of the present invention;
[0046] Figure 4 The effect of combining sibutramine first and then combining methyl parathion at different concentrations on the inhibition rate provided by one embodiment of the present invention;
[0047] Figure 5 This is the ultraviolet scanning identification curve of the methyl parathion-sibutramine artificial antigen obtained in Example 3 of the present invention;
[0048] Figure 6 The indirect competition ELISA standard curve of the methyl parathion polyclonal antibody obtained in Example 5 of the present invention;
[0049] Figure 7 This is the sibutramine polyclonal antibody indirect competition ELISA standard curve obtained in Example 5 of the present invention. DETAILED DESCRIPTION
[0050] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0051] According to a first aspect of the present invention, there is provided a methyl parathion hapten, the structural formula of which is shown in formula (I):
[0052]
[0053] The methyl parathion hapten of the present invention is named as 4-(diethoxythiophosphate)benzoic acid by using the systematic nomenclature.
[0054] The methyl parathion hapten provided by the invention can obtain a novel artificial antigen structure after being coupled with a carrier protein.
[0055] According to a second aspect of the present invention, there is provided a method for preparing the above-mentioned methyl parathion hapten, comprising the following steps:
[0056] O,O-Diethylthiophosphoryl chloride reacts with p-hydroxybenzoic acid to obtain methyl parathion hapten.
[0057] In the present invention, p-hydroxybenzoic acid is linked to O,O-diethylthiophosphoryl chloride to form methyl parathion hapten (4-(diethoxythiophosphorothioate)benzoic acid), that is, the structure shown in formula (I).
[0058] In the present invention, O,O-diethylthiophosphoryl chloride is added dropwise to a mixed solution of p-hydroxybenzoic acid, potassium hydroxide and methanol, stirred at 0° C. for reaction, and then filtered and purified to obtain methyl parathion hapten.
[0059] The method for preparing the methyl parathion hapten provided by the invention has simple process and high success rate.
[0060] A typical preparation method of methyl parathion hapten, see Figure 1 , including the following steps:
[0061] (1) adding O,O-diethylphosphorylthiochloride dropwise to a mixture of p-hydroxybenzoic acid, potassium hydroxide and methanol, stirring and filtering the mixture, and removing the solvent under reduced pressure;
[0062] (2) adding distilled water, extracting with chloroform several times, then acidifying the liquid with hydrochloric acid, and extracting with chloroform several times again;
[0063] (3) The chloroform solution is concentrated under reduced pressure and chromatographically separated to obtain the methyl parathion hapten.
[0064] In a preferred embodiment, in step (1), the mass volume ratio of O,O-diethylphosphorothioyl chloride, p-hydroxybenzoic acid, potassium hydroxide and methanol can be 2.26g:1.38g:1.40g:50mL, but is not limited thereto, which is more conducive to further improving the reaction effect.
[0065] In a preferred embodiment, in step (1), the stirring temperature is 0°C and the stirring time is 12 hours.
[0066] In a preferred embodiment, in step (2), the volume mass ratio of distilled water added to the solute can be 20 mL: 2.26 g, but is not limited thereto, which is more conducive to further improving the extraction effect.
[0067] In a preferred embodiment, in step (2), the concentration of hydrochloric acid can be 6 mol / L, but is not limited thereto.
[0068] In a preferred embodiment, in step (3), the chromatography column may be silica gel, and the chromatography liquid may be CHCl3-MeOH (6:1), but is not limited thereto.
[0069] According to the third aspect of the present invention, there is provided a sibutramine hapten, the structural formula of which is shown in formula (II):
[0070]
[0071] The sibutramine hapten of the present invention is named by systematic nomenclature: 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
[0072] The sibutramine hapten provided by the present invention can obtain a novel artificial antigen structure after being coupled with a carrier protein.
[0073] According to a fourth aspect of the present invention, there is provided a method for preparing the above-mentioned sibutramine hapten, comprising the following steps:
[0074] 1-(4-chlorophenyl)cyclobutanecarbonitrile reacts with isobutylmagnesium bromide and sodium borohydride to obtain sibutramine hapten.
[0075] In the present invention, 4-chlorobenzeneacetonitrile and 1,3-dibromopropane react to generate 1-(4-chlorophenyl)cyclobutanecarbonitrile, and 1-(4-chlorophenyl)cyclobutanecarbonitrile reacts with isobutylmagnesium bromide and sodium borohydride to generate sibutramine hapten (1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine), i.e., the structure shown in formula (II).
[0076] In the present invention, dimethyl sulfoxide containing potassium hydroxide is dripped into an ether solution containing 4-chlorophenylacetonitrile and 1,3-dibromopropane, and washed to obtain a colorless oily substance 1-(4-chlorophenyl)cyclobutanecarbonitrile; magnesium powder, isobutyl bromide and ether are mixed to obtain an isobutyl magnesium bromide solution; 1-(4-chlorophenyl)cyclobutanecarbonitrile is dripped into the isobutyl magnesium bromide solution, the ether is evaporated, and then an isopropanol suspension containing sodium borohydride is added, the solvent is evaporated, and then extracted with ethyl acetate, and dried over anhydrous magnesium sulfate to obtain sibutramine hapten.
[0077] The method for preparing the sibutramine hapten provided by the invention has simple process and high success rate.
[0078] A typical preparation method of sibutramine hapten, schematic diagram is shown in Figure 2 , including the following steps:
[0079] (1) Pour 4-chlorobenzeneacetonitrile, 1,3-dibromopropane and diethyl ether into a constant pressure funnel, and add a dimethyl sulfoxide solution containing potassium hydroxide dropwise while stirring. After the addition is complete, add ice water and diethyl ether, filter, and wash the filter residue with diethyl ether;
[0080] (2) pouring the washing liquid and the filtrate into a separatory funnel, discarding the water layer, extracting the oil layer with ether, washing with water, drying over anhydrous magnesium sulfate, evaporating the ether and distilling under reduced pressure to obtain 1-(4-chlorophenyl)cyclobutanecarbonitrile;
[0081] (3) Add magnesium powder to a three-necked flask, and dropwise add anhydrous ether and isobutyl bromide while stirring to obtain an isobutyl magnesium bromide solution;
[0082] (4) dissolving 1-(4-chlorophenyl)cyclobutanecarbonitrile in toluene, and then dropping the mixture into an isobutylmagnesium bromide solution, while distilling off the ether, stirring the mixture, and then adding a hot sodium borohydride-isopropanol mixture, heating to reflux, and then leaving at room temperature, and evaporating the solvent using a rotary evaporator;
[0083] (5) The solute obtained by evaporation is mixed with water and allowed to stand, extracted with ethyl acetate, the ester layer is washed with water and then dried over anhydrous magnesium sulfate, and the solvent is evaporated to obtain sibutramine hapten.
[0084] In a preferred embodiment, in step (1), the mass volume ratio of 4-chlorobenzeneacetonitrile, 1,3-dibromopropane and diethyl ether can be 15.15 g:21.2 g:50 mL, but is not limited thereto, which is more conducive to further improving the reaction effect.
[0085] In a preferred embodiment, in step (1), the stirring temperature can be 20°C-25°C, nitrogen needs to be introduced during stirring, and the stirring time can be during the dropwise addition and 30 minutes after the dropwise addition, which is more conducive to further improving the reaction effect.
[0086] In a preferred embodiment, in step (1), the mass volume ratio of potassium hydroxide to dimethyl sulfoxide can be 9.6 g:30 mL, but is not limited thereto.
[0087] In a preferred embodiment, in step (1), the volume ratio of ice water to diethyl ether can be 20 mL:100 mL, but is not limited thereto.
[0088] In a preferred embodiment, in step (1), the filtered material may be diatomaceous earth.
[0089] In a preferred embodiment, in step (2), the volume ratio of ether to water can be 100 mL:100 mL, but is not limited thereto.
[0090] In a preferred embodiment, in step (2), the number of extractions with diethyl ether can be 2 times, but is not limited thereto.
[0091] In a preferred embodiment, in step (2), the number of washing with water can be 3 times, but is not limited thereto.
[0092] In a preferred embodiment, in step (2), the temperature condition of the reduced pressure distillation can be 168°C-169°C, and the pressure condition can be 2666Pa.
[0093] In a preferred embodiment, in step (3), the mass volume ratio of magnesium powder, anhydrous ether and isobutyl bromide can be 4.8g:80mL:31.5g, but is not limited thereto, which is more conducive to the full generation of isobutyl magnesium bromide.
[0094] In a preferred embodiment, in step (4), the mass volume ratio of 1-(4-chlorophenyl)cyclobutanecarbonitrile and toluene can be 25 g:100 mL, but is not limited thereto.
[0095] In a preferred embodiment, in step (4), the mass volume ratio of sodium borohydride to isopropanol can be 15 g:500 mL, but is not limited thereto.
[0096] In a preferred embodiment, in step (4), the heating reflux time can be 6 hours, but not limited thereto; the room temperature storage time can be 18 hours, but not limited thereto.
[0097] In a preferred embodiment, in step (5), the volume ratio of water, ethyl acetate and washing water can be 500 mL:100 mL:100 mL, but not limited thereto; and the standing time can be 30 min, but not limited thereto.
[0098] In a preferred embodiment, in step (5), the number of extractions with ethyl acetate can be 3 times, but not limited thereto; the number of washings with water can be 2 times, but not limited thereto.
[0099] According to the fifth aspect of the present invention, there is provided a methyl parathion-sibutramine artificial antigen, which is obtained by coupling the above-mentioned methyl parathion hapten and the above-mentioned sibutramine hapten with a carrier protein through the active ester method.
[0100] The methyl parathion-sibutramine artificial antigen provided by the present invention is a novel artificial antigen structure. The polyclonal antibody obtained from the artificial antigen can simultaneously recognize methyl parathion and sibutramine, and has a good recognition ability.
[0101] In a preferred embodiment, the carrier protein may be bovine serum albumin (BSA) and chicken ovalbumin (OVA).
[0102] The first preparation method: first couple the methyl parathion hapten with BSA / OVA, then couple it with the sibutramine hapten, and construct images of different hapten concentrations and inhibition rates, see Figure 3 , calculate the optimal concentration ratio and inhibition rate. The second preparation method: first couple the sibutramine hapten with BSA / OVA, and then couple it with methyl parathion hapten to obtain an image, see Figure 4 , calculate the optimal concentration ratio and inhibition rate. Comparing the two inhibition rates obtained, the final result shows that the inhibition rate of first combining with methyl parathion hapten with a concentration ratio of 8.65:1 (methyl parathion: sibutramine) is better, so the first preparation method is selected to prepare methyl parathion-sibutramine artificial antigen.
[0103] By coupling the two haptens with OVA / BSA successively, the effects of the binding order and the concentration ratio of the two drugs on the inhibition rate were explored to obtain the optimal coupling method; the haptens were coupled with the carrier protein according to methyl parathion-BSA / OVA-sibutramine to obtain artificial antigens.
[0104] It can be seen that the present invention provides a new idea for preparing the best spectrum antibody by exploring the influence of the binding sequence and concentration ratio of two haptens on the inhibition rate.
[0105] A typical preparation method of methyl parathion-sibutramine artificial antigen comprises the following steps:
[0106] First, the methyl parathion hapten shown in formula (I) is coupled with a carrier protein by an active ester method, and then the obtained conjugate is coupled with the sibutramine hapten shown in formula (II) by an active ester method. After dialysis, the methyl parathion-sibutramine artificial antigen is obtained.
[0107] According to the sixth aspect of the present invention, there is provided a methylparathion-sibutramine polyclonal antibody obtained by immunizing an animal with any of the artificial antigens described above.
[0108] The methyl parathion-sibutramine polyclonal antibody provided by the present invention can simultaneously identify two drugs, methyl parathion and sibutramine, with good specificity and high sensitivity, provides core raw materials for establishing a specific immunoassay method for methyl parathion and sibutramine, and has broad development prospects.
[0109] The methyl parathion-sibutramine artificial antigen was emulsified and then used to immunize rabbits. The rabbit serum was collected and separated and purified by salting-out method to obtain the methyl parathion-sibutramine polyclonal antibody.
[0110] In a preferred embodiment, the salting-out method may be an octanoic acid-saturated ammonium sulfate salting-out method.
[0111] A typical preparation method of methyl parathion-sibutramine polyclonal antibody comprises the following steps:
[0112] First, the methyl parathion-sibutramine artificial antigen was emulsified with Freund's complete adjuvant in a volume ratio of 1:1, and then rabbits were immunized. Then, an equal volume of the methyl parathion-sibutramine artificial antigen was emulsified with Freund's incomplete adjuvant. The immunization was boosted every three weeks, for a total of three boosters. One week after the third booster immunization, rabbit serum was collected and the antibody was purified using the caprylic acid-saturated ammonium sulfate salt method to obtain the methyl parathion-sibutramine polyclonal antibody.
[0113] The polyclonal antibody provided by the present invention has a half inhibitory concentration (IC 50 ) was 4.59 ng / mL, the quantitative detection range was 2.89 ng / mL-7.28 ng / mL, and the detection limit was 2.21 ng / mL; the half inhibition concentration (IC 50 ) was 59.76ng / mL, the quantitative detection range was 37.65ng / mL-94.87ng / mL, and the detection limit was 28.73ng / mL.
[0114] According to a seventh aspect of the present invention, there is provided a use of the above-mentioned methyl parathion-sibutramine polyclonal antibody in immunodetection of methyl parathion and sibutramine.
[0115] The application of the methyl parathion-sibutramine polyclonal antibody provided by the present invention solves the technical problem that there is a lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art.
[0116] According to an eighth aspect of the present invention, a detection kit for methyl parathion and sibutramine is provided, the detection kit comprising the above-mentioned methyl parathion-sibutramine polyclonal antibody.
[0117] The detection kit for methyl parathion and sibutramine provided by the invention can simultaneously identify two drugs, methyl parathion and sibutramine, and has good specificity and high sensitivity.
[0118] According to a ninth aspect of the present invention, there is provided a use of the above-mentioned detection kit in immunoassay of methyl parathion and sibutramine.
[0119] The application of the detection kit for methyl parathion and sibutramine provided by the invention solves the technical problem of lack of a highly sensitive and rapid method for simultaneously detecting methyl parathion and sibutramine in the prior art.
[0120] The present invention is further described below by way of examples. Unless otherwise specified, the materials in the examples are prepared according to existing methods or directly purchased from the market.
[0121] Example 1
[0122] A method for preparing methyl parathion hapten comprises the following steps:
[0123] (1) 2.26 g of O,O-diethylphosphorylthiochloride was added dropwise to a mixture containing 1.38 g of p-hydroxybenzoic acid, 1.4 g of potassium hydroxide and 50 mL of methanol. The mixture was stirred at 0° C. for 12 h, then filtered and the solvent was removed under reduced pressure.
[0124] (2) Add 20 mL of distilled water, extract with chloroform several times, acidify with 6 mol / L hydrochloric acid, and then extract with chloroform several times;
[0125] (3) The chloroform solution was concentrated under reduced pressure and purified by column chromatography (silica gel, CHCl3-MeOH (6:1)) to obtain methyl parathion hapten.
[0126] Example 2
[0127] A method for preparing a sibutramine hapten comprises the following steps:
[0128] Preparation of 1-(4-chlorophenyl)cyclobutanecarbonitrile:
[0129] (1) Pour 9.6 g of potassium hydroxide and 30 mL of dimethyl sulfoxide into a 100 mL three-necked flask, dissolve 15.15 g of 4-chlorobenzeneacetonitrile and 21.2 g of 1,3-dibromopropane in 50 mL of ether and pour into a 100 mL constant pressure funnel, and stir thoroughly at 20°C-25°C;
[0130] (2) The solution in the constant pressure funnel was slowly dripped into the three-necked flask while nitrogen was passed through. Stirring was continued for 30 min after the dripping was completed, and then 20 mL of ice water and 100 mL of ether were added dropwise;
[0131] (3) The mixture was filtered through diatomaceous earth, the filter residue was washed with ether, the filtrate and the washing liquid were combined into a separatory funnel, the aqueous layer was discarded, the oil layer was extracted twice with 100 mL of ether, the ether layers were combined, washed three times with 100 mL of water, and dried over anhydrous magnesium sulfate;
[0132] (4) evaporating the ether in the mixture, and distilling the residual orange oil under reduced pressure (168° C.-169° C., 2666 Pa) to obtain colorless 1-(4-chlorophenyl)cyclobutanecarbonitrile;
[0133] Preparation of isobutylmagnesium bromide:
[0134] Add 4.8 g of magnesium powder to a three-necked flask, add 80 mL of anhydrous ether dropwise while stirring, and then slowly add 31.5 g of isobutyl bromide to obtain an isobutyl magnesium bromide solution;
[0135] Preparation of 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine:
[0136] (1) Dissolve 25 g of 1-(4-chlorophenyl)cyclobutanecarbonitrile in 100 mL of dry toluene, then drip into the isobutylmagnesium bromide solution, while distilling off ether. Adjust the dripping speed so that all ether is evaporated when the dripping is completed;
[0137] (2) The mixture was stirred at 90° C. for 18 h and then added to 500 mL of isopropanol containing 15 g of hot sodium borohydride. The mixture was heated under reflux for 6 h and then allowed to stand at room temperature for 18 h before the solvent was evaporated using a rotary evaporator.
[0138] (3) Add 500 mL of water to the residue and mix well. Let stand for 30 min, extract three times with 100 mL of ethyl acetate, wash the ester layer twice with 100 mL of water, dry over anhydrous magnesium sulfate, and evaporate the solvent to obtain a light yellow sibutramine hapten.
[0139] Example 3
[0140] A methyl parathion-sibutramine artificial antigen and its synthesis method and identification:
[0141] Synthesis of methyl parathion-sibutramine artificial antigen:
[0142] (1) Weigh 4.5 mg of methyl parathion hapten, 2 mg of NHS, and 3 mg of EDC, dissolve them in 100 uL of DMF, and stir overnight;
[0143] (2) Weigh 9.4 mg of bovine serum albumin (BSA) and add it to 1 mL of PBS buffer;
[0144] (3) Slowly adding the solution obtained in step (1) dropwise to the solution obtained in step (2) and stirring for 8 h;
[0145] (4) dialyzing with PBS buffer for two days, four times a day, and obtaining methyl parathion-BSA artificial antigen after the dialysis is completed;
[0146] (5) Weigh 11.2 mg of sibutramine hapten, 2 mg of NHS, and 3 mg of EDC, dissolve in 100 μL of DMF, and stir overnight;
[0147] (6) Slowly add the solution obtained in step (5) dropwise to the solution obtained in step (4) and stir for 8 h;
[0148] (7) dialyzing with PBS buffer for two days, four times a day, and obtaining methyl parathion-BSA-sibutramine artificial antigen after the dialysis;
[0149] Formula of phosphate buffer solution: Na2HPO4·12H2O 2.90g, NaCl 8.50g, KCl 0.20g, KH2PO40.20g, add distilled water to make up to 1000mL;
[0150] Similarly, chicken ovalbumin (OVA) was used to replace BSA as a carrier protein to obtain the target product, methyl parathion-OVA-sibutramine artificial antigen, and its preparation process was the same as that of the preparation of methyl parathion-BSA-sibutramine artificial antigen;
[0151] Identification of the Methylparathion-Sibutramine Artificial Antigen:
[0152] Take methyl parathion-sibutramine artificial antigen and perform UV full wavelength scanning, such as Figure 5 shown.
[0153] BSA, OVA, and artificial antigens were respectively identified by UV (200nm-400nm) scanning, and the maximum absorbance values of each substance before and after coupling were compared. The absorption curve of the methyl parathion-sibutramine artificial antigen was significantly different from that of the carrier protein, indicating that the haptens of methyl parathion and sibutramine were successfully coupled with the carrier protein to produce artificial antigens.
[0154] Example 4
[0155] A method for preparing a methyl parathion-sibutramine polyclonal antibody comprises the following steps:
[0156] (1) New Zealand white rabbits were immunized with methyl parathion-BSA-sibutramine as the immunogen. During the initial immunization, the immunogen was emulsified with Freund's complete adjuvant at a volume ratio of 1:1 to immunize the rabbits. Subsequently, the immunogen was emulsified with Freund's incomplete adjuvant at a volume ratio of 1:1, and booster immunization was performed every three weeks for a total of three booster immunizations.
[0157] (2) One week after the third booster immunization, rabbit serum was collected and centrifuged at 4°C and 12,000 rpm for 15 min to remove the precipitate;
[0158] (3) 1 volume of the supernatant was mixed with 2 volumes of acetate buffer, the pH was adjusted to 4.8, 75 μL of octanoic acid was added dropwise while stirring, the mixture was stirred at room temperature for 30 min, and then allowed to stand at 4 °C for 2 h;
[0159] (4) Centrifuge at 4°C and 12,000 r / min for 15 min, filter the supernatant, add 1 / 10 volume of PBS buffer (0.1 M, pH 7.4) to the supernatant, adjust the pH to 7.4 with 2 M sodium hydroxide, and calculate the total volume of the solution;
[0160] (5) Add 0.28 g / mL of ammonium sulfate within 30 min under ice bath to make a 45% saturated solution, let stand at 4°C for 1 h, centrifuge at 4°C and 12,000 r / min for 15 min, discard the supernatant, and dialyze the precipitate against PBS buffer (0.1 M, pH 7.4) for three days to obtain methyl parathion-sibutramine polyclonal antibody.
[0161] Example 5
[0162] ELISA test of methyl parathion-sibutramine polyclonal antibody and its results:
[0163] ELISA test:
[0164] (1) Dilute the original methyl parathion-OVA-sibutramine with coating solution to 0.125 ng / mL, coat the ELISA plate, add 100 μL to each well, incubate at 37°C overnight, discard the coating solution, and wash twice;
[0165] (2) Add 120 μL of blocking solution (5% skim milk powder) to each well and block at 37°C for 30 min. Discard the blocking solution, tap the plate, and dry at 37°C for later use.
[0166] (3) Dilute the antibody serum 16K-fold with PBST, and dilute the methyl parathion standard and sibutramine standard from 1 μg / mL to 0.001 ng / mL with PBST;
[0167] (4) Add 50 μL of methyl parathion dilution to each row of columns 1-3 (three parallel groups), add 50 μL of sibutramine dilution to each row of columns 4-6 (three parallel groups), then add 50 μL of antibody dilution to each well, incubate at 37°C for 40 min, and wash 5 times;
[0168] (5) Add goat anti-rabbit enzyme-labeled secondary antibody (5000-fold dilution), incubate at 37°C for 30 min, wash 5 times, and tap;
[0169] (6) Add color developing solution and develop color for 10 min;
[0170] (7) Add 50 μL of 10% H2SO4 to terminate the reaction and read the OD value at 450 nm;
[0171] Results: The standard curve of methyl parathion-sibutramine polyclonal antibody indirect competition ELISA is as follows: Figure 6 and Figure 7 As shown;
[0172] The half inhibitory concentration (IC50) of methyl parathion-sibutramine polyclonal antibody against methyl parathion 50 ) was 4.59 ng / mL, and the quantitative detection linear range (IC 20 -IC 80 ) was 2.89ng / mL-7.28ng / mL, and the minimum detection limit was 2.21ng / mL; the half inhibition concentration (IC 50 ) was 59.76 ng / mL, and the quantitative detection linear range (IC 20 -IC 80 ) was 37.65ng / mL-94.87ng / mL, and the minimum detection limit was 28.73ng / mL.
[0173] It can be seen that the methyl parathion-sibutramine polyclonal antibody of the present invention can meet the detection requirements and has good recognition ability for both methyl parathion and sibutramine.
[0174] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A methyl parathion hapten, characterized in that The structural formula of the methyl parathion hapten is shown in formula (I):
2. A method for preparing the methyl parathion hapten according to claim 1, characterized in that: The following steps are involved: O,O-diethylthiophosphoryl chloride reacts with p-hydroxybenzoic acid to obtain the methyl parathion hapten.
3. A sibutramine hapten, characterized in that: The structural formula of the sibutramine hapten is shown in formula (II):
4. A method for preparing the sibutramine hapten according to claim 3, characterized in that: The following steps are involved: 1-(4-chlorophenyl)cyclobutanecarbonitrile reacts under the action of isobutylmagnesium bromide and sodium borohydride to obtain the sibutramine hapten.
5. A methyl parathion-sibutramine artificial antigen, characterized in that: The hapten is obtained by coupling the methyl parathion hapten described in claim 1 and the sibutramine hapten described in claim 3 with a carrier protein through an active ester method.
6. The artificial antigen according to claim 5, characterized in that The carrier proteins include bovine serum albumin and chicken ovalbumin.
7. A methyl parathion-sibutramine polyclonal antibody, characterized in that: The antigen is obtained by immunizing an animal with the artificial antigen according to claim 5 or 6.
8. Use of the methyl parathion-sibutramine polyclonal antibody according to claim 7 in immunoassay of methyl parathion and sibutramine.
9. A detection kit for methyl parathion and sibutramine, characterized in that: The detection kit comprises the methyl parathion-sibutramine polyclonal antibody according to claim 7.
10. Use of the detection kit according to claim 9 in immunoassay of methyl parathion and sibutramine.
Citation Information
Patent Citations
Enzyme-linked immunologic detection method of sibutramine hydrochloride
CN101413946A
Preparation of carbaryl and methyl parathion universal antibody and universal envelope antigen
CN101475637A
Preparation of monoclonal antibody of specific combined sibutramine and demethylated sibutramine
CN101643506A
Organophosphorus hapten, wide-spectrum polyspecific antigen, antibody and preparation method and application of hapten, antigen and antibody
CN107337690A
Fenfluramine hapten, and preparation method therefor and use thereof, fenfluramine hapten artificial antigen, and fenfluramine hapten antibody
WO2023102750A1
